TriSalus cuts 2026 revenue outlook on salesforce disruption and TriNav Advance FDA delay
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $29.43M | $18.51M | $12.40M | $8.40M | N/A |
| Cost of Revenue | $4.10M | $2.60M | $2.26M | $1.19M | N/A |
| Gross Profit | $25.33M | $15.91M | $10.14M | $7.21M | N/A |
| Gross Margin | 86.06% | 85.93% | 81.79% | 85.80% | 0.00% |
| Operating Expenses | $61.49M | $70.38M | $46.58M | $31.24M | $108.49K |
| Operating Income | $-36.16M | $-54.48M | $-36.44M | $-24.03M | $-108.49K |
| Operating Margin | -122.88% | -294.28% | -293.91% | -286.06% | 0.00% |
| Net Income | $-33.23M | $-59.36M | $-47.19M | $-28.84M | $-31.83M |
| Net Margin | -112.92% | -320.69% | -380.60% | -343.35% | 0.00% |
| EPS (Basic) | $-1.25 | $-2.23 | $-1.59 | $-0.92 | $-0.02 |
| EBITDA | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A |